Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells - PubMed (original) (raw)
. 2017 Oct 19;36(42):5829-5839.
doi: 10.1038/onc.2017.188. Epub 2017 Jun 12.
Affiliations
- PMID: 28604752
- DOI: 10.1038/onc.2017.188
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells
J Feng et al. Oncogene. 2017.
Abstract
The clinical success of immunotherapy that inhibits the negative immune regulatory pathway programmed cell death protein 1/PD-1 ligand (PD-1/PD-L1) has initiated a new era in the treatment of metastatic cancer. PD-L1 expression is upregulated in many solid tumors including lung cancer and functions predominantly in lactate-enriched tumor microenvironments. Here, we provided evidence for PD-L1 induction in response to lactate stimulation in lung cancer cells. Lactate-induced PD-L1 induction was mediated by its receptor GPR81. The silencing of GPR81 signaling in lung cancer cells resulted in a decrease in PD-L1 protein levels and functional inactivation of PD-L1 promoter activity. In addition, GPR81-mediated upregulation of PD-L1 in glucose-stimulated lung cancer cells that recapitulates the enhanced glycolysis in vivo was dependent on lactate dehydrogenase A (LDHA). We also demonstrated that activation of GPR81 decreases intracellular cAMP levels and inhibits protein kinase A (PKA) activity, leading to activation of the transcriptional coactivator TAZ. Interaction of TAZ with the transcription factor TEAD was essential for TAZ activation of PD-L1 and induction of its expression. Furthermore, we found that lactate-induced activation of PD-L1 in tumor cells led to reduced production of interferon-γ and induction of apoptosis of cocultured Jurkat T-cell leukemia cells. Our findings reveal an unexpected role of lactate in contributing to tumor cell protection from cytotoxic T-cell targeting and establishes a direct connection between tumor cell metabolic reprograming and tumor evasion from the immune response.
Similar articles
- The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ, Yang X. Janse van Rensburg HJ, et al. Cancer Res. 2018 Mar 15;78(6):1457-1470. doi: 10.1158/0008-5472.CAN-17-3139. Epub 2018 Jan 16. Cancer Res. 2018. PMID: 29339539 - Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, Lu JJ. Yuan LW, et al. Phytomedicine. 2021 Jan;80:153394. doi: 10.1016/j.phymed.2020.153394. Epub 2020 Oct 22. Phytomedicine. 2021. PMID: 33130472 - Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin.
Chen S, Zhou X, Yang X, Li W, Li S, Hu Z, Ling C, Shi R, Liu J, Chen G, Song N, Jiang X, Sui X, Gao Y. Chen S, et al. Biomolecules. 2021 Sep 17;11(9):1373. doi: 10.3390/biom11091373. Biomolecules. 2021. PMID: 34572586 Free PMC article. - Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon.
Brown TP, Ganapathy V. Brown TP, et al. Pharmacol Ther. 2020 Feb;206:107451. doi: 10.1016/j.pharmthera.2019.107451. Epub 2019 Dec 10. Pharmacol Ther. 2020. PMID: 31836453 Review. - Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC, Jablons DM, Yang CT, You L. Hsu PC, et al. Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821. Int J Mol Sci. 2019. PMID: 31387256 Free PMC article. Review.
Cited by
- The regulation of immune checkpoints by the hypoxic tumor microenvironment.
Hu M, Li Y, Lu Y, Wang M, Li Y, Wang C, Li Q, Zhao H. Hu M, et al. PeerJ. 2021 May 7;9:e11306. doi: 10.7717/peerj.11306. eCollection 2021. PeerJ. 2021. PMID: 34012727 Free PMC article. - Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma.
Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S, Wang Y. Xu Y, et al. Front Oncol. 2023 Jan 6;12:1063423. doi: 10.3389/fonc.2022.1063423. eCollection 2022. Front Oncol. 2023. PMID: 36686771 Free PMC article. Review. - Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy.
Tao H, Zhong X, Zeng A, Song L. Tao H, et al. Front Immunol. 2023 Jul 26;14:1208870. doi: 10.3389/fimmu.2023.1208870. eCollection 2023. Front Immunol. 2023. PMID: 37564659 Free PMC article. Review. - Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J, Mygland L, Tveita A, Strand MF, Solberg NT, Olsen PA, Aizenshtadt A, Fauskanger M, Lund K, Brinch SA, Lycke M, Dybing E, Nygaard V, Bøe SL, Heintz KM, Hovig E, Hammarström C, Corthay A, Krauss S. Waaler J, et al. Commun Biol. 2020 Apr 24;3(1):196. doi: 10.1038/s42003-020-0916-2. Commun Biol. 2020. PMID: 32332858 Free PMC article. - Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy.
Baltazar F, Afonso J, Costa M, Granja S. Baltazar F, et al. Front Oncol. 2020 Mar 18;10:231. doi: 10.3389/fonc.2020.00231. eCollection 2020. Front Oncol. 2020. PMID: 32257942 Free PMC article. Review.
References
- Mol Pharmacol. 2011 Nov;80(5):848-58 - PubMed
- Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed
- Cell. 2016 Mar 10;164(6):1233-1247 - PubMed
- Cancer Res. 2014 Feb 1;74(3):665-74 - PubMed
- Nat Rev Cancer. 2016 May;16(5):275-87 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous